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Abstract: Glycyrrhizic acid (GA) ameliorates many components of the metabolic syndrome, 
but its potential therapeutic use is marred by edema caused by inhibition of renal 11β-
hydroxysteroid dehydrogenase 2 (11β-HSD2). We assessed whether 100 mg/kg per day GA 
administered orally could promote metabolic benefits without causing edema in rats fed on 
a high-sucrose diet. Groups of eight male rats were fed on one of three diets for 28 days: 
normal diet, a high-sucrose diet, or a high-sucrose diet supplemented with GA. Rats were 
then culled and renal 11β-HSD2 activity, as well as serum sodium, potassium, angiotensin II 
and leptin levels were determined. Histological analyses were performed to assess changes 
in adipocyte size in visceral and subcutaneous depots, as well as hepatic and renal tissue 
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morphology. This dosing paradigm of GA attenuated the increases in serum leptin levels and 
visceral, but not subcutaneous adipocyte size caused by the high-sucrose diet. Although GA 
decreased renal 11β-HSD2 activity, it did not affect serum electrolyte or angiotensin II 
levels, indicating no onset of edema. Furthermore, there were no apparent morphological 
changes in the liver or kidney, indicating no toxicity. In conclusion, it is possible to reap 
metabolic benefits of GA without edema using the current dosage and treatment time. 
Keywords: glycyrrhizic acid; metabolic syndrome; high-sucrose diet; 11β-HSD2;  
side effects; edema; angiotensin II; electrolytes 
 
1. Introduction 
Metabolic syndrome is a breakdown of various metabolic functions resulting in abnormalities that 
pose a significant risk for cardiovascular disease and type II diabetes mellitus [1]. The characteristic 
aberrations of the metabolic syndrome include central obesity, hyperglycaemia, hypertension, insulin 
resistance and dyslipidaemia [2]. Over the past decades, decreased exercise due to improvements in 
technology, combined with the spread of westernized diets, have caused a significant increase in the 
incidence of metabolic syndrome in developed and developing countries alike [2]. Westernized diets 
include primarily those high in energy content, from both fat and sucrose. High-sucrose feeding alone 
has been shown to trigger many of the abnormalities of the metabolic syndrome [3]. Although there are 
several drugs available to treat the components of the metabolic syndrome, many of those that are 
commonly available tend to be expensive—particularly for people in developing countries—and/or 
associated with numerous side-effects [4–7]. Hence the search for alternate substances that could 
prevent/reverse the onset and progression of the metabolic syndrome has become increasingly important. 
One potential treatment for the metabolic syndrome is glycyrrhizic acid (GA), which is the primary 
bioactive constituent of licorice, obtained from the root of the Glycyrrhiza glabra shrub [8]. Our research 
has indicated various benefits of GA consumption in rats fed on either a high-fat [9] or high sucrose diet 
(HSD) [3]. These benefits include reductions in circulating concentrations of glucose and insulin, 
enhanced insulin sensitivity, improved circulating lipid profiles, and favorable alterations in the 
expression of genes and activity of enzymes involved in lipid metabolism and energy balance [3,9,10]. 
The dose of GA required to bring about metabolic benefits depends on the duration and route of 
administration, as previously reviewed [11]. 
The potential of GA to treat the metabolic syndrome stems primarily from its ability to inhibit the 
enzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) [11]. However, this action is non-selective, 
as GA also inhibits the other isoform of this enzyme, 11β-HSD2 [11]. The two isoforms of 11β-HSD 
have been shown to have opposing functions, which is of vital consequence with regards to the effects 
of GA consumption. 11β-HSD2 is a dehydrogenase that catalyzes the reversible conversion of active 
glucocorticoids (corticosterone in rats, cortisol in humans) to their inactive derivatives (11β-
dehydrocorticosterone in rats, cortisone in humans) [12]. On the other hand, 11β-HSD1 can act both as 
a dehydrogenase, to catalyze the deactivation of glucocorticoids, as well as a reductase, to catalyze the 
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activation of glucocorticoids [12,13]. In intact cells, the reductase actions of 11β-HSD1 that result in 
glucocorticoid activation have been shown to be more potent than their dehydrogenase actions [12]. 
As seen from the above, inhibition of 11β-HSD1 by GA will be expected to result in increased 
production of inactive glucocorticoids relative to active glucocorticoids. This brings about many of the 
benefits of GA with regards to the metabolic syndrome [3,9]. However, the concurrent inhibition of  
11β-HSD2 by GA is potentially detrimental, as it could lead to edema, hypertension and hypokalemia, 
all of which have been observed as side effects in some instances of GA administration in humans and 
animals [11,14]. This is because the expression of 11β-HSD2 is highest in tissues that are targeted 
significantly by aldosterone, such as the kidneys, which have an abundance of mineralocorticoid 
receptors [12]. As the affinity of mineralocorticoid receptors for glucocorticoids and aldosterone is 
similar [14], the presence of higher concentrations of active glucocorticoids—as occurs with GA-induced 
suppression of 11β-HSD 2 [14]—could lead to their competitive binding to mineralocorticoid receptors, 
leading to a syndrome of apparent mineralocorticoid excess [14–16]. This is presented in the form of 
electrolyte imbalances, which are responsible for the afore-mentioned side effects [14]. This can also 
depress the renin-angiotensin aldosterone system (RAAS) and increase the levels of atrial natriuretic 
peptide in order to compensate for the changes in water balance caused by fluctuations in electrolyte 
levels [17]. Furthermore, in some cases, these side effects could also be brought about by the action of 
glycyrrhetinic acid, the primary metabolite of GA, via direct action on mineralocorticoid receptors [18,19]. 
Initial manifestation of GA-induced side effects are generally associated with 11β-HSD2 suppression, 
while side effects caused by direct effects of glycyrrhetinic acid are evident when serum concentrations 
of the latter are consistent with its affinity for mineralocorticoid receptors [19]. It is for the above reasons 
that, despite its known metabolic benefits as shown in animal models, GA is not yet a viable treatment 
option for disorders of the metabolic syndrome. The side effects of GA vary depending on the route of 
administration [11]. For example, while topical GA application significantly reduced subcutaneous fat 
levels in healthy women with no change in blood pressure or circulating renin activity, aldosterone or 
cortisol levels [20], oral GA administration to healthy men and women caused significant fat loss along 
with water retention, thereby leading to no significant reduction in the body-mass index [21]. In addition, 
the side effects of GA consumption are clearly dose-dependent, with lower doses inducing lesser, or no 
side effects relative to higher doses [22]. As in the case of metabolic benefits, the lowest dose at which 
side effects appear to manifest is dependent upon the duration and route of administration. For example, 
the toxicity of a given dose of GA is greater when administered for longer durations, and when 
administered subcutaneously or intraperitoneally, compared to topical or oral administrations [11]. 
Metabolic benefits of GA on lipid metabolism in rats on a normal chow diet were apparent at doses 
as low as 50 mg/kg per day for one week [10]. Unpublished data from our lab, however, indicated that 
GA at 100 mg/kg per day for four weeks was more effective at improving metabolic parameters, 
especially in rats exhibiting components of the metabolic syndrome due to consumption of high-fat or 
high sucrose diets. Since we have established many benefits of GA consumption with regards to the 
metabolic syndrome at a dose of 100 mg/kg per day for four weeks in rats fed on a HSD [3], it is 
important to assess how this dosage fares in terms of potential side effects. With such information we 
could establish whether it would be possible to reap the favorable effects of GA while minimizing 
detrimental effects, thus increasing its viability as a treatment option for the metabolic syndrome. 
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A previous study from our team showed that oral GA administration at 100 mg/kg per day for  
four weeks to rats on a HSD induced metabolic benefits without any increase in blood pressure, albeit 
blood pressure remained significantly greater than that of control rats on a normal chow diet in both 
HSD and HSD + GA groups [3]. This indicated that high-sucrose feeding increased blood pressure 
relative to control levels, while oral GA administration at this dose and duration did not exacerbate  
diet-induced hypertension. However, the possible onset of early precursors to hypertension, such as 
hypokalemia (a deficiency of potassium in the bloodstream) and edema, were not examined in that study. 
In the current study, performed over the same duration and at the same dosage in high sucrose-fed rats, we 
thus examined kidney 11β-HSD2 activity levels, as its inhibition could cause many of the side effects of 
GA, as discussed above. Serum electrolyte (Na+, K+) levels were also examined, as changes in their 
concentrations are associated with edema [11,14], as well as the possibility of the eventual development 
of hypertension [11,14]. Furthermore, as depression of the RAAS is observable in cases of 
mineralocorticoid excess syndrome [17], we also analyzed our GA-treated sucrose-fed rats for serum 
levels of angiotensin II, which is responsible for the activation of aldosterone. Potential toxic effects of 
GA consumption at the current dose and duration of administration on the liver and kidney were also 
examined by histological analyses. Finally, we analyzed how GA at this dosage would affect food intake, 
circulating leptin levels, and adipocyte size in both subcutaneous and visceral depots in sucrose-fed rats. 
As leptin is a major regulator of energy homeostasis, assessing the effects of GA on leptin along  
with adipocyte size may give further clues on the overall mechanism of action of GA with regard to  
metabolic benefits. 
2. Experimental Section 
2.1. Treatment of Rats and Sample Collection 
2.1.1. Animal Ethics 
Approval to use rats for the purpose of this experiment was obtained from the Monash University 
School of Biomedical Science Animal Ethics Committee (approval number: MARP/2012/043; approval 
date: 8 May 2012), according to the 2004 Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes and the Monash University Animal Welfare Committee Guidelines and Policies 
(Prevention of Cruelty to Animals Act 1986). 
2.1.2. Animal Preparation 
Twenty-four male Sprague Dawley rats of approximately 180 g–220 g (~7 weeks old) were purchased 
from the animal breeding facility of Monash University Sunway Campus, Malaysia. Only male rats were 
included in the study cohort to avoid any effects of cyclical changes in hormones in female rats. Rats 
were 6–8 weeks old upon commencement of the study and housed individually in polypropylene cages 
of approximately 35 × 25 × 20 cm. The cages contained shredded paper bedding. 
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2.1.3. Experimental Design 
The 24 rats were divided randomly into three equal groups: Chow, High Sucrose Diet (HSD) and 
HSD + GA. Rats in the Chow group were fed standard rat chow (Gold Coin, Selangor, Malaysia).  
The HSD was prepared by mixing powdered rat chow with cane sugar (Gula Prai, Prai, Malaysia) at a 
2:3 ratio. Ten milliliter of water was added to the mixture, which was mixed to form a thick dough. 
Pellets were formed by hand and then baked at 160 °C for 5 min and then stored at 4 °C. All rats were 
given ad libitum access to food for the 28 days of the experiment, unless otherwise stated. The amount 
of food consumed over the past 24 h was evaluated at approximately 09:00 each day, and the average 
food consumption over the course of the treatment period was used to measure mean energy intake  
per day for each group. While rats in the Chow and HSD groups were given tap water to drink  
ad libitum, those in the HSD + GA group were given tap water with GA, designed to deliver 100 mg of 
GA per kg bodyweight per day based on average body weight and mean water consumption in the 
preceding week by the rats in that group. The GA-containing water was freshly prepared each week. All 
water bottles were topped to 250 mL every week, and the amount of water consumed over the past 24 h 
was evaluated at approximately 09:00 each day. 
2.1.4. Collection of Tissue Samples 
At the end of 28 days on the 3 different diets, all 24 rats were fasted for 12 h and then anaesthetized 
with intraperitoneal sodium pentobarbital (150 mg/kg) between 10:00 and 11:00. 
Using a 5 mL syringe with a 22 G needle, blood was drawn from the apex of the heart, left to stand 
for 20 min to clot at room temperature, and then centrifuged at 12,000× g for 10 min at 4 °C. The 
resulting serum was stored at −80 °C until needed. 
The four tissues of interest, namely the subcutaneous and visceral adipose tissue (SAT and VAT), 
liver and kidney were harvested. Portions of the kidney samples from each animal were weighed, minced 
and placed immediately into separate 15 mL Falcon tubes containing ice-cold Krebs-Ringer bicarbonate 
(KRB) buffer (2 mL per g of tissue) for the measurement of 11β-HSD2 activities. Sections of the kidney, 
liver, SAT and VAT obtained from each animal were also washed, cut into approximately 5 × 5 × 5 mm 
pieces, and immersed in 10% neutral-buffered formalin for subsequent histological analysis. 
2.2. Determination of 11β-Hydroxysteroid Dehydrogenase 2 Activity 
Determination of 11β-HSD2 activity was conducted by quantifying the amount of 11-
dehydrocorticosterone produced from externally administered corticosterone by the enzyme present in 
a fixed mass of kidney tissue. 
Kidney tissues collected as described above were homogenized and then centrifuged at 4 °C and 
14,000× g for 20 min. Protein concentrations in tissue homogenate supernatants were determined using 
the modified Lowry’s method. Supernatants containing 50 mg of tissue protein were mixed with the 
substrate mixture for 11-βHSD2, and then KRB buffer was used to top up the reaction mixture to 500 µL, 
giving a final concentration of 0.35 mmol/L NAD+, 0.1 mmol/L corticosterone, 0.2% glucose, 0.2% bovine 
serum albumin and 5% ethanol. Reaction mixtures were incubated for 1 h at 37 °C and were then 
immediately placed into a −20 °C freezer in order to terminate the reaction, and stored there until the 
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next step. Next, 800 μL of ethyl acetate was pipetted into each microcentrifuge tube and tubes were 
mixed in an orbital shaker at 100 RPM for 30 min at room temperature. The samples were then 
centrifuged at 16,000× g and room temperature for 10 min. The upper (organic) layer of the centrifuged 
samples were separated and added to a new microcentrifuge tube, and ethyl acetate was evaporated using 
flowing nitrogen gas. Dried content was stored at −20 °C until quantification of glucocorticoids using 
high-performance liquid chromatography (HPLC). Reverse-phase chromatography was used to separate 
corticosterone (substrate) from 11-dehydrocorticosterone (product). Three-hundred microliter of HPLC 
mobile phase (20% methanol, 30% acetonitrile and 50% water v/v) was added to each microcentrifuge 
tube containing the dried glucocorticoid content. A series of cortisone (11-dehydrocorticosterone 
equivalent) standards were used to make a standard curve. A 100 µL Hamilton HPLC syringe was used 
to inject 30 µL of standard or sample into a 20 µL sample loop of the Perkin Elmer 200 Liquid 
Chromatography pump (Shelton, CT, USA). A Waters Symmetry® C18 column (Tokyo, Japan) with 
dimensions 3.9 mm (diameter) × 150 mm (length) was used for separation of sample glucocorticoids. A 
linear methanol-acetonitrile-water gradient from 10:15:75 (v/v) to 20:30:50 (v/v) in the first 5 min was 
employed to separate the glucocorticoids. Isocratic elution then followed for the next 10 min. The 
constant flow rate of the mobile phase was set at 1.00 mL/min. Spectrophotometric absorbance was 
measured at 254 nm. Enzyme activity was expressed in units (U), in which 1 U of 11β-HSD2 activity is 
defined as one picomole of 11-dehydrocorticosterone produced per 50 mg of tissue protein used, per h 
of incubation at 37 °C. 
2.3. Determination of Serum Angiotensin II and Leptin Levels 
Serum angiotensin II and leptin levels were determined using the AGT/Agt (Human, Rat, Mouse) 
ELISA kit from Abnova (Taipei City, Taiwan) and the Millipore (Rat, Mouse) ELISA kit (Billerica, MA, 
USA) respectively, according to the manufacturers’ manuals. 
2.4. Electrolyte Concentration Determination 
Electrolyte concentrations in serum were determined using atomic absorption spectrophotometry and 
the Beer-Lambert law. 
2.4.1. Serum Sodium Ion Level Determination 
A series of standard sodium solutions were used to make a standard curve. Blank and standard solutions 
were aspirated and measured with the Perkin Elmer Atomic Absorption spectrophotometer Analyst 100 
(Waltham, MA, USA) using a sodium/potassium hollow cathode lamp at 589.0 nm. 
Two-hundred microliter of serum was diluted to 100 mL with distilled water in a volumetric flask. 
These samples were then aspirated into the spectrophotometer and the concentration of sodium in the 
serum was calculated from comparison with the standard curve. 
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2.4.2. Serum Potassium Ion Level Determination 
The method to determine serum potassium levels was similar to that used to measure serum sodium 
levels, with the exception that the 200 µL serum was diluted in 10 mL of distilled water, and the 
wavelength used was 766.5 nm. 
2.5. Histological Analyses 
Analyses were conducted to examine liver and kidney tissue morphology and to assess the size of 
subcutaneous and visceral adipocytes. The haematoxylin and eosin stain (H & E stain) was used for 
these purposes. H & E-stained SAT and VAT sections were viewed using Olympus BX51 microscope 
(New York, NY, USA). The sizes of 25 adipocytes (µm2) per tissue section per field view for five views 
were measured using the Nikon Instruments-Element D 2.30 software (Nikon Instruments Inc., Melville, 
NY, USA). 
2.6. Statistical Analysis 
Statistical analysis of all data was performed using Statistical Package for the Social Sciences (SPSS) 
Version 16.0. Data distribution was analyzed using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Data 
with parametric distribution were analyzed using Analysis of Variance (ANOVA). If the results were 
significant, a Post Hoc (Tukey’s) test was performed to identify differences. Non-parametric data were 
analyzed using the Kruskall-Wallis test. In all analyses, a p value ≤ 0.05 was considered to be  
statistically significant. 
3. Results 
3.1. Glycyrrhizic Acid Intake Ameliorated the Effects of a High-Sucrose Diet on Serum Leptin Levels 
and Adipocyte Size 
Our studies have previously shown that GA consumption attenuates the effects of a HSD to increase 
serum glucose and insulin levels [3]. Further metabolic effects of this dose of GA (100 mg/kg per day 
administered orally for four weeks) were assessed by examining effects on leptin levels and adipocyte 
size. Although GA did not attenuate the increased energy intake induced by the HSD (Figure 1A), it 
reduced serum leptin levels significantly (Figure 1B). GA intake also prevented adipocyte hypertrophy 
caused by the HSD in the visceral but not the subcutaneous adipose tissue depots, as shown in  
Figure 1C,D. These results, combined with those obtained by Chandramouli et al. [3], indicate the 
potential for significant modulative capabilities of GA at the current dose and duration, with regard to 
metabolic parameters. 
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Figure 1. Glycyrrhizic acid consumption ameliorated effects of a high-sucrose diet on 
metabolic parameters. (A) Daily energy intake and (B) serum leptin concentrations, as well 
as (C) representative examples of haemotoxylin and eosin (H & E) stained sections of 
subcutaneous and visceral adipose tissue (SAT and VAT, 200× magnification) and  
(D) adipocyte size (cross-sectional area) in SAT and VAT depots from rats fed normal chow, 
a high-sucrose diet (HSD), or a HSD supplemented with 100 mg/kg per day glycyrrhizic acid 
(HSD + GA), administered orally for four weeks. One unit (U) of 11β-HSD2 activity is 
defined as one picomole of 11-dehydrocorticosterone produced per 50 mg of tissue protein 
used, per h of incubation at 37 °C. Data are means ± SEM of 8 male rats per group.  
* p ≤ 0.05, ** p ≤ 0.01 for the comparison shown by horizontal bars. 
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3.2. Glycyrrhizic Acid Did Not Change Circulating Levels of Electrolytes or Renin Angiotensin II, or 
Alter Liver or Kidney Histomorphology, Despite Reducing Kidney 11β-HSD2 Activity 
As mentioned in the introduction, the primary side effects of GA are hypertension and edema, which 
are caused by increased water retention resulting from electrolyte imbalances caused by inhibition of 
renal 11β-HSD2 activity [14]. Water retention also causes a compensatory decrease in the RAAS  
activity [17]. Although our dose of 100 mg/kg per day GA consumption for four weeks attenuated the 
effects of the HSD on metabolic parameters as described above, and although this dose of GA 
significantly decreased the activity of 11β-HSD2 in the kidney of rats in the HSD + GA group relative 
to that in the chow or high sucrose fed rats (Figure 2A), it did not result in electrolyte imbalances as 
indicated by alterations in serum concentrations of angiotensin II (Figure 2B) or the electrolytes sodium 
or potassium (Figure 2C), relative to rats fed on a HSD. This suggests that the current dose and treatment 
time of GA used in this study did not affect renal 11β-HSD2 activities significantly enough to alter these 
parameters over and above the effects of the HSD. Furthermore, haemotoxylin and eosin stained tissue 
sections showed no change in hepatic or kidney tissue morphology (Figure 2D), indicating no visible 
toxic effects on these organs during metabolism and excretion of GA. 
Figure 2. Glycyrrhizic acid consumed at the given dosage did not lead to signs of changes 
in fluid balance despite reduced kidney 11β-HSD2 activity. (A) Kidney 11β-HSD2 activity; 
(B) serum angiotensin II concentrations; (C) serum electrolyte concentrations ((a):sodium; 
(b):potassium), and (D) representative samples of haemotoxylin and eosin (H & E) stained 
sections of liver and kidney (×200 magnification) from rats fed normal chow, a high-sucrose 
diet (HSD), or a HSD supplemented with 100 mg/kg per day glycyrrhizic acid (HSD + GA), 
administered orally for four weeks. Data are means ± SEM of 8 male rats per group. * p ≤ 0.05, 
** p ≤ 0.01 for the comparison shown by horizontal bars. 
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Figure 2. Cont. 
 
 
4. Discussion 
Despite its known therapeutic potential for metabolic disorders, GA consumption is still not used as 
a mainstream therapy for the metabolic syndrome due to its side effects of edema and hypertension. In 
this study, we found that a daily oral dosage of 100 mg/kg per day GA administered for four weeks 
significantly averted metabolic deviations associated with a HSD in rats without any concomitant 
indication of side effects associated with previous GA paradigms. Indeed, GA prevented the increases 
in adipocyte size and circulating leptin levels caused by a HSD, despite no effect on energy intake. No 
apparent changes in electrolyte balance (as indicated by serum sodium or potassium concentrations) or 
serum levels of angiotensin II were detected with GA consumed for the duration of this study at the 
current dose, despite a significant decrease in kidney 11β-HSD2 activity. Furthermore, no changes in 
liver or kidney histomorphology were apparent, suggesting no toxic effect of this dosing paradigm of 
GA on these tissues. These results suggest that by carefully modulating dosage and treatment time, GA 
could be a potentially safe therapeutic agent against metabolic changes associated with a HSD. 
The inhibition of renal 11β-HSD2 activity by GA is known to be a primary cause of the undesirable 
side effects associated with GA intake [11,14]. As mentioned in the introduction, this effect has  
been shown to increase renal sodium reabsorption and potassium excretion, thereby increasing water 
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retention [14]. This in turn brings about the two major side effects that have been associated with GA 
intake: edema and hypertension [14]. This experiment however suggests no such change in electrolyte 
balance with the consumption of 100 mg/kg per day GA for four weeks, despite significant reductions 
in renal 11β-HSD2 levels. This indicates that the major side-effects associated with GA intake would 
not have occurred, suggesting that suppression of renal 11β-HSD2 activity by GA was not detrimental 
with the present dosing paradigm. Indeed, we have previously shown that there was no change in blood 
pressure with GA intake under the same paradigms used in this study [3]. It is hence likely that  
11β-HSD2 activities were not sufficiently reduced with the current dosing paradigm, and/or were not 
reduced for a sufficient duration, to cause an adequate increase in active glucocorticoids, such as would 
be necessary to cause a hyper-mineralocorticoid effect and subsequent edema and hypertension. It is also 
important to note that even if edema and hypertension were to occur at some point beyond four weeks, 
studies show that it would be reversed after GA administration had ceased [23–25]. 
It is possible that the expected increase in the proportion of active glucocorticoids caused by a 
reduction in renal 11β-HSD2, which would influence parameters affecting blood pressure, may have 
been countered at least partially by a concomitant reduction in renal 11β-HSD1 activity. Indeed, a 
previous publication [3] showed a significant drop in renal 11β-HSD1 activity with this same dose and 
duration of GA administration in rats on a HSD. Moreover, the reductase effects of 11β-HSD1 to activate 
glucocorticoids is stronger than its dehydrogenase actions to inactivate glucocorticoids in intact  
cells [12,13], so such a decrease in 11β-HSD1 activity would be expected to shift the balance towards 
inactive glucocorticoids, which could have countered any adverse effects of reduced 11β-HSD2 activity 
on blood pressure regulation with the current dosing paradigm. If such a countering effect of reductions 
in 11β-HSD1 versus reductions in 11β-HSD2 activity is occurring at the present dose of GA in rats on a 
HSD, it is not evident at higher doses of GA, as it is well established that GA, above a certain dosage, 
indeed brings about edema and hypertension [14]. 
Another hypothetical explanation for the lack of adverse effects of this dose of GA on electrolyte 
balance or circulating angiotensin II levels is that the high sucrose diet may be able to block the effects 
of GA at the level of the mineralocorticoid receptors. While this possibility cannot be excluded  
at present, we believe it is unlikely because unpublished data from our group indicate that blood  
pressure remains unchanged with GA administration via the same dosing paradigm in rats that are fed a 
high fat instead of a high sucrose diet. Moreover, while high sucrose diets per se are known to  
markedly and significantly increase blood pressure in rats [3], this effect is likely mediated by the 
hyperinsulinemia induced by such diets [3,26] rather than via effects on mineralocorticoid receptors. 
Indeed, hyperinsulinaemia has been shown to stimulate the RAAS in blood vessels and the heart [27,28], 
ultimately leading to the overproduction of angiotensin II in these tissues [29]. It has also been shown 
that high levels of insulin directly enhance the expression and production of angiotensinogen [30], which, 
with the availability of renin, leads to an increased amount of angiotensin II. Furthermore, 
hyperinsulinaemia is linked to up-regulation of angiotensin converting enzyme (ACE) activity [31], 
which is responsible for the conversion of angiotensin I into angiotensin II. The important point from 
the current study, with respect to the potential safety of orally-administered GA, is that while high 
sucrose diets lead to increased blood pressure, likely involving effects of hyperinsulinemia, GA—with 
its known effects on glucocorticoid balance—does not further exacerbate HSD-induced hypertension, 
when administered with the current dosing paradigm. 
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Despite the fact that GA administered at the dose and duration of this study did not cause any apparent 
changes in fluid balance, nor the RAAS, as would be expected during development of side effects, the 
current GA dosing paradigm was able to maintain metabolic benefits associated with its intake. This dose 
of GA (100 mg/kg per day, orally administered) has been shown to prevent aberrations in glucose and 
lipid metabolism caused by a HSD [3]. The current study further extends these findings by showing that 
GA prevented the HSD-induced increases in adipocyte size and circulating leptin levels without changing 
caloric intake. Although there was no change in energy intake, the ability of GA to prevent 
hyperinsulinaemia associated with a HSD, as shown by Chandramouli et al. [3], would likely have 
contributed to the attenuation of leptin levels, as insulin is known to be a major stimulator of leptin 
secretion [32,33]. Furthermore, there is a link between hyperleptinaemia and adipocyte hypertrophy, and 
therefore the ability of GA to restrain adipocyte size, as shown in the visceral but not subcutaneous 
depots in this study, could have also contributed to the observed modulation of leptin levels. This is 
because leptin biosynthesis increases under conditions of obesity, due in part to enhanced post- and  
pre-transcriptional effects of insulin and glucocorticoids [34]. The decrease in visceral adipocyte size 
with GA intake despite no change in energy intake could be attributed at least partially to the decrease in 
circulating insulin levels, as well as to the increase in lipoprotein lipase (LPL) expression in multiple 
tissues including the liver, kidney, muscle tissue and white adipose tissue [3]. Such a change could lead 
to a competitively increased uptake of free fatty acids into non-adipose tissues and a consequentially 
smaller amount of circulating lipids available for accumulation in adipose tissue [35]. In addition, 
substances such as thiazolidinediones which can activate peroxisome proliferator-activated receptor γ 
(PPARγ) in adipose tissue, a capability also shown by GA [3], has been shown to stimulate differentiation 
of preadipocytes, generating an increased number of smaller adipocytes that are more insulin-sensitive 
and efficient at storing lipids [36–38]. This has been shown to lead to improved insulin sensitivity in the 
skeletal muscle, probably by reducing circulating free fatty acids and skeletal muscle triglycerides [39]. 
This may also, in part, be responsible for the reduction of adipocyte size in the visceral depots seen in 
the current study. PPARγ agonists have also been shown to redistribute fat from visceral to subcutaneous 
depots, which would explain the lack of a significant difference in subcutaneous adipocyte size despite 
decreased circulating insulin and increased LPL expression [40]. 
5. Conclusions 
Prevalence of the metabolic syndrome has vastly increased over the past 50 years and this in turn is 
largely responsible for the greater incidence of metabolic diseases such as cardiovascular disease and 
type II diabetes mellitus. Many of the treatments for the metabolic syndrome today are expensive and/or 
associated with side effects. When considering the metabolic benefits of GA seen in this experiment and 
our previous studies [3,9], GA appears to have potential as a viable treatment option for many metabolic 
disorders associated with the metabolic syndrome, provided that the dosage and duration of treatment is 
carefully monitored to minimize the known side-effects of fluid imbalance leading to alterations in the 
RAAS and, subsequently, edema and hypertension. However, it cannot be excluded that edema and 
hypertension may have eventuated with a longer duration of GA administration, so it would therefore be 
necessary to understand how long it would take for such side effects to manifest (if at all), by testing 
longer treatment durations. Furthermore, as it is already understood that stopping GA intake reverses 
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any side effects which have already developed [29–31], it would be necessary to study exactly how long 
such a reversal would take, and also to what extent any metabolic benefits obtained from GA 
consumption would be maintained after discontinuation. Such knowledge would aid in developing a 
model for a treatment plan, in order to maximize metabolic benefits and minimize side effects of  
GA consumption. 
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